Insider Trading Alert - KALU, CCRN And CVGW Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 15, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $428.00 to $1,771,500.00.

Highlighted Stocks Traded by Insiders:

Kaiser Aluminum (KALU) - FREE Research Report

Donnan John Malcolm, who is EVP - Legal, Compliance & HR at Kaiser Aluminum, sold 1,500 shares at $83.88 on June 15, 2015. Following this transaction, the EVP - Legal, Compliance & HR owned 24,577 shares meaning that the stake was reduced by 5.75% with the 1,500-share transaction.

Harvey Keith, who is EVP - Fabricated Products at Kaiser Aluminum, sold 1,500 shares at $83.17 on June 15, 2015. Following this transaction, the EVP - Fabricated Products owned 45,984 shares meaning that the stake was reduced by 3.16% with the 1,500-share transaction.

The shares most recently traded at $83.70, up $0.53, or 0.63% since the insider transaction. Historical insider transactions for Kaiser Aluminum go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 8,500
  • 24-Week # shares sold: 16,900

The average volume for Kaiser Aluminum has been 197,300 shares per day over the past 30 days. Kaiser Aluminum has a market cap of $1.4 billion and is part of the basic materials sector and metals & mining industry. Shares are up 17.5% year-to-date as of the close of trading on Monday.

Kaiser Aluminum Corporation, together with its subsidiaries, produces semi-fabricated specialty aluminum products. The stock currently has a dividend yield of 1.9%. Currently, there are 6 analysts who rate Kaiser Aluminum a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KALU - FREE

TheStreet Quant Ratings rates Kaiser Aluminum as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Kaiser Aluminum Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cross Country Healthcare (CCRN) - FREE Research Report

Anenberg Vickie, who is Pres., Cross Country Staffing at Cross Country Healthcare, sold 13,563 shares at $11.73 on June 15, 2015. Following this transaction, the Pres., Cross Country Staffing owned 142,275 shares meaning that the stake was reduced by 8.7% with the 13,563-share transaction.

The shares most recently traded at $12.23, up $0.50, or 4.09% since the insider transaction. Historical insider transactions for Cross Country Healthcare go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 7,000

The average volume for Cross Country Healthcare has been 183,100 shares per day over the past 30 days. Cross Country Healthcare has a market cap of $382.1 million and is part of the services sector and diversified services industry. Shares are down 4.81% year-to-date as of the close of trading on Monday.

Cross Country Healthcare, Inc. provides healthcare staffing and workforce solutions in the United States. The company operates through three segments: Nurse and Allied Staffing, Physician Staffing, and Other Human Capital Management Services. Currently, there are 3 analysts who rate Cross Country Healthcare a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CCRN - FREE

TheStreet Quant Ratings rates Cross Country Healthcare as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Cross Country Healthcare Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Calavo Growers (CVGW) - FREE Research Report

Cole Lecil E, who is Chairman, CEO & President at Calavo Growers, sold 400 shares at $55.00 on June 15, 2015. Following this transaction, the Chairman, CEO & President owned 752,652 shares meaning that the stake was reduced by 0.05% with the 400-share transaction.

The shares most recently traded at $54.72, down $0.28, or 0.51% since the insider transaction. Historical insider transactions for Calavo Growers go as follows:

  • 4-Week # shares sold: 29,242
  • 12-Week # shares sold: 29,242
  • 24-Week # shares sold: 29,242

The average volume for Calavo Growers has been 104,200 shares per day over the past 30 days. Calavo Growers has a market cap of $945.8 million and is part of the consumer goods sector and food & beverage industry. Shares are up 14.97% year-to-date as of the close of trading on Monday.

Calavo Growers, Inc. markets, and distributes avocados, prepared avocados, and other perishable foods to food distributors, produce wholesalers, supermarkets, convenience stores, and restaurants worldwide. It operates in three segments: Fresh Products, Calavo Foods, and RFG. The stock currently has a dividend yield of 1.38%. The company has a P/E ratio of 67.2. Currently, there are 2 analysts who rate Calavo Growers a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVGW - FREE

TheStreet Quant Ratings rates Calavo Growers as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Calavo Growers Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Stocks Search for Direction as Trump Comments Lead to Worries Over China Talks

Stocks Search for Direction as Trump Comments Lead to Worries Over China Talks

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

Italy's President Gives Mandate For Anti-European Government in Rome

Italy's President Gives Mandate For Anti-European Government in Rome